Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Optimer presents CDI drug phase 3 trials data
In two Phase 3 trials for the treatment of CDI, fidaxomicin was non-inferior in clinical cure when compared to vancomycin, the only FDA approved product for CDI. The
In two Phase 3 trials for the treatment of CDI, fidaxomicin was non-inferior in clinical cure when compared to vancomycin, the only FDA approved product for CDI. The
As per the terms of the research collaboration and option agreement, Pepscan will utilize its Chemical LInkage of Peptides onto Scaffolds (CLIPS) technology for optimizing novel therapeutic Phylomer
The company is engaged in the commercialization of its proprietary Capture Compound Mass Spectrometry (CCMS) technology in the areas of functional proteomics, drug development and development of biomarkers.
Regorafenib is indicated as a treatment for patients who are suffering from metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite at least imatinib and
Typical applications range from small-scale protein expression to media or process optimization studies UniVessel SU is made up of USP class VI conform polycarbonate and is suitable for
The company has reported a net loss of $1.22m, or $0.02 loss per diluted share, compared to net loss of $1.05m or $0.02 loss per diluted share, for
The company has reported a net income was $6.48m, or $0.02 per diluted share, compared to a net loss of $3.15m, or $0.02 loss per diluted share, for
The study results suggested that the adult patients evaluated with Cimzia that achieved early responses were found to have an increased chance of achieving longer-term outcomes. In the
The company has reported a net loss of $1.38m, or $0.02 loss per diluted share, compared to net loss of $1.61m or $0.02 loss per diluted share, for
SimpleCTMS is intended to offer the benefits of a CTMS (Clinical Trial Management System) without the extensive upfront financial and resource commitments associated with traditional enterprise systems or